PE20141166A1 - Anticuerpos anti-angptl3 y usos de los mismos - Google Patents
Anticuerpos anti-angptl3 y usos de los mismosInfo
- Publication number
- PE20141166A1 PE20141166A1 PE2013002804A PE2013002804A PE20141166A1 PE 20141166 A1 PE20141166 A1 PE 20141166A1 PE 2013002804 A PE2013002804 A PE 2013002804A PE 2013002804 A PE2013002804 A PE 2013002804A PE 20141166 A1 PE20141166 A1 PE 20141166A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- hangptl3
- refers
- variable region
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical group O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UN ANTICUERPO HUMANO AISLADO QUE SE FIJA ESPECIFICAMENTE A LA PROTEINA 3 HUMANA DE TIPO ANGIOPOYETINA (HANGPTL3) DE SEQ ID NO: 161 Y NEUTRALIZA, REDUCE, O INTERFIERE CON LA ACTIVIDAD DE HANGPTL3. DICHO ANTICUERPO SE FIJA A UN EPITOPE SITUADO DENTRO DE LA REGION DE SERPENTIN ENROLLADO N-TERMINAL EN LOS RESIDUOS 17-209 DE SEQ ID NO: 161. ASI MISMO EL ANTICUERPO COMPRENDE UNA REGION VARIABLE DE CADENA PESADA SELECCIONADA DEL GRUPO CONSTITUIDO POR SEQ ID NO: 2, 18,34, ENTRE OTROS, Y UNA REGION VARIABLE DE CADENA LIGERA SELECCIONADA DEL GRUPO SEQ ID N�:10, 26.42, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE PRODUCCION DE DICHO ANTICUERPO Y A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498518P | 2011-06-17 | 2011-06-17 | |
| US201161578309P | 2011-12-21 | 2011-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141166A1 true PE20141166A1 (es) | 2014-09-16 |
Family
ID=46298728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002804A PE20141166A1 (es) | 2011-06-17 | 2012-06-14 | Anticuerpos anti-angptl3 y usos de los mismos |
Country Status (46)
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2017011929A1 (zh) * | 2015-07-17 | 2017-01-26 | 北京大学第一医院 | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MX2018009680A (es) * | 2016-02-17 | 2018-09-10 | Regeneron Pharma | Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3. |
| MX2018010401A (es) * | 2016-03-03 | 2019-03-06 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
| CN109789194B (zh) * | 2016-04-08 | 2022-08-02 | 瑞泽恩制药公司 | 用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法 |
| IL262591B (en) * | 2016-04-28 | 2022-07-01 | Regeneron Pharma | Treatment methods for patients with hereditary high blood cholesterol |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CA3044249A1 (en) | 2016-11-17 | 2018-05-24 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-angptl8 antibodies |
| EP3967765A1 (en) | 2017-07-06 | 2022-03-16 | FrieslandCampina Nederland B.V. | Cell culture process for making a glycoprotein |
| US11977081B2 (en) | 2017-12-18 | 2024-05-07 | Regeneron Pharmaceuticals, Inc. | ANGPTL8 assay and uses thereof |
| CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| MX2020008095A (es) | 2018-01-31 | 2020-09-24 | Regeneron Pharma | Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos. |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| US12460270B2 (en) | 2018-02-28 | 2025-11-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| BR112020015291B1 (pt) | 2018-03-19 | 2023-09-26 | Regeneron Pharmaceuticals, Inc | Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| JP7511542B2 (ja) | 2018-08-30 | 2024-07-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質複合体を特徴づけるための方法 |
| EP3887393A1 (en) * | 2018-11-26 | 2021-10-06 | Novartis AG | Lpl-gpihbp1 fusion polypeptides |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| BR112021009544A2 (pt) | 2019-01-16 | 2021-10-26 | Regeneron Pharmaceuticals, Inc. | Métodos para identificar ligações dissulfeto embaralhadas em um medicamento de proteína e de produção de um medicamento de proteína, e, composição farmacêutica |
| US20220144961A1 (en) * | 2019-03-11 | 2022-05-12 | Xyence Therapeutics, Inc. | Cd27-binding antibodies and uses thereof |
| KR20220007586A (ko) | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 개선된 경쟁적 리간드 결합 검정 |
| US20200369760A1 (en) * | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| US20220380425A1 (en) * | 2019-07-04 | 2022-12-01 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| PH12022550630A1 (en) | 2019-09-24 | 2023-03-27 | Regeneron Pharma | Systems and methods for chromatography use and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN114760986A (zh) | 2019-11-25 | 2022-07-15 | 里珍纳龙药品有限公司 | 使用非水性乳液的持续释放调配物 |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| KR102544013B1 (ko) | 2020-01-21 | 2023-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 당질화된 단백질의 전기영동을 위한 탈당질화 방법 |
| CA3166346A1 (en) * | 2020-01-22 | 2021-07-29 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-angptl3 antibody and use thereof |
| EP4204578A1 (en) | 2020-08-31 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| CN116710124A (zh) | 2020-12-17 | 2023-09-05 | 瑞泽恩制药公司 | 包封蛋白质的微凝胶的制造 |
| AU2022209730A1 (en) | 2021-01-20 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
| WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| WO2022204728A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| WO2022205021A1 (zh) * | 2021-03-30 | 2022-10-06 | 复旦大学附属儿科医院 | 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途 |
| CA3220848A1 (en) | 2021-06-01 | 2022-12-08 | Timothy Riehlman | Microchip capillary electrophoresis assays and reagents |
| CN117545769A (zh) * | 2021-07-21 | 2024-02-09 | 江苏恒瑞医药股份有限公司 | 一种抗angptl3抗体或其抗原结合片段的药物组合物及其用途 |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| MX2024003411A (es) | 2021-09-20 | 2024-04-30 | Regeneron Pharma | Métodos para controlar la heterogeneidad de anticuerpos. |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| TW202330104A (zh) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法 |
| CN116284377A (zh) * | 2021-12-21 | 2023-06-23 | 复旦大学 | 抗人血管生成素3纳米抗体及其应用 |
| CA3241896A1 (en) * | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| AU2023233590A1 (en) | 2022-03-18 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| WO2023213779A1 (en) * | 2022-05-02 | 2023-11-09 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| CN117603361A (zh) * | 2022-08-22 | 2024-02-27 | 复旦大学附属儿科医院 | 包含angptl3单抗的融合蛋白 |
| CN116143919B (zh) * | 2022-11-01 | 2025-06-13 | 中国药科大学 | 全人源抗人nt-angptl3抗体、其抗原结合片段及其应用 |
| WO2024130165A1 (en) * | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| KR20250124178A (ko) | 2022-12-16 | 2025-08-19 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피 칼럼의 무결성을 평가하기 위한 방법 및 시스템 |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445135A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 液態蛋白質組成物穩定性之建模方法 |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| WO2024229136A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| CN119192369A (zh) * | 2023-06-25 | 2024-12-27 | 百奥泰生物制药股份有限公司 | 抗angptl3抗体及其应用 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| WO2025072597A2 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| CN117535353A (zh) * | 2023-10-11 | 2024-02-09 | 首都医科大学附属北京潞河医院 | 一种糖尿病视网膜病变模型的建立方法及应用 |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| WO2025096932A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| ATE357216T1 (de) | 2001-02-22 | 2007-04-15 | Jagotec Ag | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen |
| KR20100029861A (ko) | 2001-11-16 | 2010-03-17 | 제넨테크, 인크. | 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는 조성물 및 이를 사용하는 방법 |
| EP2322202A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| WO2006098887A2 (en) | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| ES2400666T5 (es) | 2005-12-16 | 2016-03-10 | Regeneron Pharmaceuticals, Inc. | Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral |
| PT2041177E (pt) | 2006-06-02 | 2012-03-05 | Regeneron Pharma | Anticorpos com elevada afinidade para o receptor il-6 humano |
| WO2008054606A2 (en) * | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| EP2121751B1 (en) | 2006-12-08 | 2017-01-25 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| EA023073B1 (ru) | 2009-07-14 | 2016-04-29 | Дзе Скриппс Рисёч Инститьют | Способы и композиции для лечения или предупреждения артрита или повреждения сустава |
| WO2011085271A2 (en) | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| ES2923573T3 (es) * | 2011-06-21 | 2022-09-28 | Alnylam Pharmaceuticals Inc | Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| PT3087183T (pt) | 2013-12-24 | 2020-10-08 | Ionis Pharmaceuticals Inc | Modulação da expressão da proteína relacionada com angiopoietina 3 |
| PL3137605T3 (pl) | 2014-05-01 | 2021-04-19 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji białka angiopoetynopodobnego 3 |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MX2018009680A (es) | 2016-02-17 | 2018-09-10 | Regeneron Pharma | Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3. |
| MX2018010401A (es) | 2016-03-03 | 2019-03-06 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
| CN109789194B (zh) | 2016-04-08 | 2022-08-02 | 瑞泽恩制药公司 | 用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法 |
| IL262591B (en) | 2016-04-28 | 2022-07-01 | Regeneron Pharma | Treatment methods for patients with hereditary high blood cholesterol |
| US20200369760A1 (en) * | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
-
2012
- 2012-06-13 JO JOP/2012/0155A patent/JO3412B1/ar active
- 2012-06-13 AR ARP120102099A patent/AR087329A1/es active IP Right Grant
- 2012-06-14 PL PL12727767T patent/PL2721065T3/pl unknown
- 2012-06-14 PT PT12727767T patent/PT2721065T/pt unknown
- 2012-06-14 UA UAA201314628A patent/UA114891C2/uk unknown
- 2012-06-14 EP EP18185031.4A patent/EP3418301A1/en not_active Withdrawn
- 2012-06-14 EP EP12727767.1A patent/EP2721065B1/en active Active
- 2012-06-14 MX MX2013014345A patent/MX337644B/es active IP Right Grant
- 2012-06-14 TR TR2018/16591T patent/TR201816591T4/tr unknown
- 2012-06-14 PH PH1/2013/502570A patent/PH12013502570B1/en unknown
- 2012-06-14 WO PCT/US2012/042338 patent/WO2012174178A1/en not_active Ceased
- 2012-06-14 AU AU2012271663A patent/AU2012271663B2/en active Active
- 2012-06-14 SG SG2013087432A patent/SG195165A1/en unknown
- 2012-06-14 ES ES12727767T patent/ES2699499T3/es active Active
- 2012-06-14 LT LTEP12727767.1T patent/LT2721065T/lt unknown
- 2012-06-14 DK DK12727767.1T patent/DK2721065T3/en active
- 2012-06-14 MX MX2015017575A patent/MX361859B/es unknown
- 2012-06-14 US US13/517,662 patent/US9018356B2/en active Active
- 2012-06-14 RS RS20181508A patent/RS58310B1/sr unknown
- 2012-06-14 SI SI201231444T patent/SI2721065T1/sl unknown
- 2012-06-14 RU RU2013155906A patent/RU2620064C2/ru active
- 2012-06-14 SM SM20180658T patent/SMT201800658T1/it unknown
- 2012-06-14 CN CN201280038908.0A patent/CN103732624B/zh active Active
- 2012-06-14 JP JP2014515976A patent/JP6400471B2/ja active Active
- 2012-06-14 CA CA2838867A patent/CA2838867C/en active Active
- 2012-06-14 HR HRP20182098TT patent/HRP20182098T1/hr unknown
- 2012-06-14 KR KR1020147000902A patent/KR102031007B1/ko active Active
- 2012-06-14 MY MYPI2013004223A patent/MY160516A/en unknown
- 2012-06-14 PE PE2013002804A patent/PE20141166A1/es active IP Right Grant
- 2012-06-15 UY UY0001034137A patent/UY34137A/es not_active Application Discontinuation
- 2012-06-15 TW TW107135714A patent/TW201920261A/zh unknown
- 2012-06-15 UY UY0001039340A patent/UY39340A/es not_active Application Discontinuation
- 2012-06-15 TW TW106123582A patent/TW201815822A/zh unknown
- 2012-06-15 TW TW101121453A patent/TWI644922B/zh active
-
2013
- 2013-11-25 IL IL229612A patent/IL229612B/en active IP Right Grant
- 2013-11-26 CR CR20130621A patent/CR20130621A/es unknown
- 2013-11-26 ZA ZA2013/08879A patent/ZA201308879B/en unknown
- 2013-12-06 NI NI201300136A patent/NI201300136A/es unknown
- 2013-12-11 GT GT201300306A patent/GT201300306A/es unknown
- 2013-12-11 DO DO2013000299A patent/DOP2013000299A/es unknown
- 2013-12-11 CL CL2013003552A patent/CL2013003552A1/es unknown
- 2013-12-13 CO CO13292222A patent/CO6821892A2/es unknown
- 2013-12-16 EC ECSP13013085 patent/ECSP13013085A/es unknown
- 2013-12-17 MA MA36579A patent/MA35190B1/fr unknown
-
2015
- 2015-03-24 US US14/667,121 patent/US9951127B2/en active Active
-
2018
- 2018-04-20 US US15/958,996 patent/US10358487B2/en active Active
- 2018-05-16 IL IL259436A patent/IL259436A/en active IP Right Grant
- 2018-07-06 JP JP2018128768A patent/JP2018166516A/ja active Pending
- 2018-12-11 CY CY181101324T patent/CY1120996T1/el unknown
-
2019
- 2019-06-07 US US16/435,032 patent/US20190315851A1/en not_active Abandoned
-
2021
- 2021-09-01 NL NL301122C patent/NL301122I2/nl unknown
- 2021-09-06 HU HUS2100034C patent/HUS2100034I1/hu unknown
- 2021-09-06 LT LTPA2021009C patent/LTC2721065I2/lt unknown
- 2021-09-09 FI FIC20210028C patent/FIC20210028I1/fi unknown
- 2021-09-15 NO NO2021037C patent/NO2021037I1/no unknown
- 2021-09-23 LU LU00231C patent/LUC00231I2/fr unknown
- 2021-12-06 CY CY2021036C patent/CY2021036I2/el unknown
- 2021-12-14 FR FR21C1061C patent/FR21C1061I2/fr active Active
-
2022
- 2022-01-27 US US17/586,662 patent/US20220153825A1/en not_active Abandoned
- 2022-09-08 US US17/930,704 patent/US20220403016A1/en not_active Abandoned
-
2024
- 2024-12-27 US US19/004,070 patent/US20250136675A1/en active Pending
-
2025
- 2025-06-13 NO NO2025028C patent/NO2025028I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| PE20141028A1 (es) | Nuevos moduladores y metodos para su uso | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| AR104809A1 (es) | Anticuerpos anti-cd40 y usos de los mismos | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| MX2021013336A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
| PE20141158A1 (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico | |
| CO6280500A2 (es) | Anticuerpos humanizados especificos pare l factor von willebrand | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
| MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| EA201792451A1 (ru) | Антитела к ox40 и способы их применения | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| EA201590294A1 (ru) | Аналоги глюкагона | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
| PE20131411A1 (es) | Anticuerpos contra la tweak humana y usos de los mismos | |
| PE20141568A1 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina | |
| PE20142168A1 (es) | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |